

Modalidad de participación:	<b>PÓSTER</b>
CÓDIGO	S10

**TÍTULO**

**Relevance of p53 expression in the hematopoietic stem cells transplantation in patients with low risk myelodysplastic syndrome**

**AUTOR/ES:**

Fernando Barroso Duarte<sup>1</sup>, Romélia Pinheiro Gonçalves Lemes<sup>2</sup>, **Maritza Cavalcante Barbosa<sup>2</sup>**, Talyta Ellen de Jesus dos Santos<sup>2</sup>, João Paulo Vasconcelos<sup>3</sup>, Francisco Dário Rocha Filho<sup>4</sup>, Paulo Roberto Leitão de Vasconcelos<sup>1</sup>

<sup>1</sup> Department of Surgery, Federal University of Ceará - Brazil

<sup>2</sup> Research Laboratory in Hemoglobinopathies and Genetics of Hematologic Diseases, Federal University of Ceará - Brazil

<sup>3</sup> Hematology Service of Walter Cantídio University Hospital - Brazil

<sup>4</sup> Department of Pathology and Legal Medicine, Federal University of Ceará - Brazil

**RESUMEN (ABSTRACT):**

**Introduction:** Hematopoietic stem cell transplantation (HSCT) is a well-established therapy for some hematologic malignancies. In Myelodysplastic Syndromes (MDS) is the only curative alternative, but many patients are not eligible due to several limiting factors, especially for patients with low-risk MDS. **Objective:** The objective of this study was to describe two cases of patients with low-risk MDS, in which the indication of HSCT, and the importance of prognostic factors, such as the expression of p53 protein was discussed. **Methods:** This is an observational and descriptive study with a qualitative approach. **Results:** Both patients had marrow fibrosis. One of the patients who had a positive p53 expression with the 40% mark. Six months after the first admission, the patient died. The other patient, which was negative for the marking of the p53 protein was submitted to HSCT and is stable and in complete remission. **Conclusion:** Allogeneic HSCT for low-risk MDS is an option and can be performed in elderly patients, with acceptable levels of mortality and morbidity related to transplantation. The findings suggest the value of p53 expression as a relevant factor in the indication of HSCT.

**PALABRAS CLAVE (KEYWORDS):**

**Keywords:** Myelodysplastic Syndrome; Hematopoietic Stem Cells Transplantation; p53